MAPT and amyloidosis: We found that targeting PD-1 or its PD-L1 ligand could modify AD pathology in a mouse model of amyloid pathology, 5XFAD, as well as in an animal model of tau pathology, expressing the human-tau gene with two mutations associated with frontotemporal dementia (DM-hTAU)31.